Condensed Consolidating Statement of Cash Flows | |||||||||||||||||||||||||||
(in millions) | Express Scripts Holding Company | Express Scripts, Inc. | Medco Health Solutions, Inc. | Guarantors | Non- Guarantors | Eliminations | Consolidated | ||||||||||||||||||||
For the year ended December 31, 2013 | |||||||||||||||||||||||||||
Net cash flows provided by (used in) operating activities | $ | (214.1 | ) | $ | 2,731.3 | $ | 765.9 | $ | 556.0 | $ | 929.1 | $ | (10.7 | ) | $ | 4,757.5 | |||||||||||
Cash flows from investing activities: | |||||||||||||||||||||||||||
Purchases of property and equipment | — | (398.3 | ) | — | (16.5 | ) | (8.2 | ) | — | (423.0 | ) | ||||||||||||||||
Proceeds from the sale of business | — | 1.6 | — | 355.3 | — | — | 356.9 | ||||||||||||||||||||
Acquisitions, net of cash acquired | — | — | — | — | (14.5 | ) | — | (14.5 | ) | ||||||||||||||||||
Other | — | 14.0 | — | — | (3.4 | ) | — | 10.6 | |||||||||||||||||||
Net cash (used in) provided by investing activities—continuing operations | — | (382.7 | ) | — | 338.8 | (26.1 | ) | — | (70.0 | ) | |||||||||||||||||
Net cash used in investing activities—discontinued operations | — | — | — | — | (2.1 | ) | — | (2.1 | ) | ||||||||||||||||||
Net cash (used in) provided by investing activities | — | (382.7 | ) | — | 338.8 | (28.2 | ) | — | (72.1 | ) | |||||||||||||||||
Cash flows from financing activities: | |||||||||||||||||||||||||||
Treasury stock acquired | (4,055.2 | ) | — | — | — | — | — | (4,055.2 | ) | ||||||||||||||||||
Repayment of long-term debt | (631.6 | ) | (1,000.0 | ) | (300.0 | ) | — | — | — | (1,931.6 | ) | ||||||||||||||||
Net proceeds from employee stock plans | 466.0 | — | — | — | — | — | 466.0 | ||||||||||||||||||||
Excess tax benefit relating to employee stock-based compensation | — | 26.6 | 16.1 | — | — | — | 42.7 | ||||||||||||||||||||
Distributions paid to non-controlling interest | — | — | — | — | (31.7 | ) | — | (31.7 | ) | ||||||||||||||||||
Other | — | — | — | (13.0 | ) | 28.0 | — | 15.0 | |||||||||||||||||||
Net intercompany transactions | 4,434.9 | (2,575.9 | ) | (478.4 | ) | (964.7 | ) | (415.9 | ) | — | — | ||||||||||||||||
Net cash (used in) provided by financing activities—continuing operations | 214.1 | (3,549.3 | ) | (762.3 | ) | (977.7 | ) | (419.6 | ) | — | (5,494.8 | ) | |||||||||||||||
Net cash used in financing activities— discontinued operations | — | — | — | — | (10.7 | ) | 10.7 | — | |||||||||||||||||||
Net cash (used in) provided by financing activities | 214.1 | (3,549.3 | ) | (762.3 | ) | (977.7 | ) | (430.3 | ) | 10.7 | (5,494.8 | ) | |||||||||||||||
Effect of foreign currency translation adjustment | — | — | — | — | (5.7 | ) | — | (5.7 | ) | ||||||||||||||||||
Less cash attributable to discontinued operations | — | — | — | — | 13.4 | — | 13.4 | ||||||||||||||||||||
Net (decrease) increase in cash and cash equivalents | — | (1,200.7 | ) | 3.6 | (82.9 | ) | 478.3 | — | (801.7 | ) | |||||||||||||||||
Cash and cash equivalents at beginning of year | — | 2,346.6 | — | 126.9 | 319.6 | — | 2,793.1 | ||||||||||||||||||||
Cash and cash equivalents at end of year | $ | — | $ | 1,145.9 | $ | 3.6 | $ | 44.0 | $ | 797.9 | $ | — | $ | 1,991.4 | |||||||||||||
Condensed Consolidating Statement of Cash Flows | |||||||||||||||||||||||||||
(in millions) | Express Scripts Holding Company | Express Scripts, Inc. | Medco Health Solutions, Inc. | Guarantors | Non- Guarantors | Eliminations | Consolidated | ||||||||||||||||||||
For the year ended December 31, 2012 | |||||||||||||||||||||||||||
Net cash flows provided by (used in) operating activities | $ | (147.3 | ) | $ | 655.1 | $ | 3,355.4 | $ | 916.7 | $ | 1.7 | $ | — | $ | 4,781.6 | ||||||||||||
Cash flows from investing activities: | |||||||||||||||||||||||||||
Purchases of property and equipment | — | (70.0 | ) | — | (85.9 | ) | (4.3 | ) | — | (160.2 | ) | ||||||||||||||||
Proceeds from the sale of business | — | 31.5 | 30.0 | — | — | — | 61.5 | ||||||||||||||||||||
Acquisitions, net of cash acquired | (10,283.6 | ) | — | — | — | (42.4 | ) | — | (10,326.0 | ) | |||||||||||||||||
Other | — | (5.0 | ) | — | — | 1.0 | — | (4.0 | ) | ||||||||||||||||||
Net cash (used in) provided by investing activities—continuing operations | (10,283.6 | ) | (43.5 | ) | 30.0 | (85.9 | ) | (45.7 | ) | — | (10,428.7 | ) | |||||||||||||||
Acquisitions, cash acquired— discontinued operations | — | — | — | — | 42.4 | — | 42.4 | ||||||||||||||||||||
Net cash used in investing activities— discontinued operations | — | — | — | (3.8 | ) | (1.6 | ) | — | (5.4 | ) | |||||||||||||||||
Net cash (used in) provided by investing activities | (10,283.6 | ) | (43.5 | ) | 30.0 | (89.7 | ) | (4.9 | ) | — | (10,391.7 | ) | |||||||||||||||
Cash flows from financing activities: | |||||||||||||||||||||||||||
Repayment of long-term debt | (1,368.4 | ) | (1,000.1 | ) | (1,500.0 | ) | — | — | — | (3,868.5 | ) | ||||||||||||||||
Net proceeds from employee stock plans | 295.2 | — | 30.8 | — | — | — | 326.0 | ||||||||||||||||||||
Excess tax benefit relating to employee stock-based compensation | — | 37.2 | 8.1 | — | — | — | 45.3 | ||||||||||||||||||||
Distributions paid to non-controlling interest | — | — | — | — | (8.1 | ) | — | (8.1 | ) | ||||||||||||||||||
Proceeds from long-term debt, net of discounts | 7,458.9 | — | — | — | — | — | 7,458.9 | ||||||||||||||||||||
Repayment of revolving credit line, net | — | — | (1,000.0 | ) | — | — | — | (1,000.0 | ) | ||||||||||||||||||
Proceeds from accounts receivable financing facility | — | — | — | — | 600.0 | — | 600.0 | ||||||||||||||||||||
Repayment of accounts receivable financing facility | — | — | — | — | (600.0 | ) | — | (600.0 | ) | ||||||||||||||||||
Deferred financing fees | (52.4 | ) | (50.8 | ) | — | — | — | — | (103.2 | ) | |||||||||||||||||
Net intercompany transactions | 4,097.6 | (2,773.5 | ) | (924.3 | ) | (705.5 | ) | 305.7 | — | — | |||||||||||||||||
Net cash provided by (used in) financing activities—continuing operations | 10,430.9 | (3,787.2 | ) | (3,385.4 | ) | (705.5 | ) | 297.6 | — | 2,850.4 | |||||||||||||||||
Net cash used in financing activities— discontinued operations | — | — | — | — | (26.8 | ) | — | (26.8 | ) | ||||||||||||||||||
Net cash provided by (used in) financing activities | 10,430.9 | (3,787.2 | ) | (3,385.4 | ) | (705.5 | ) | 270.8 | — | 2,823.6 | |||||||||||||||||
Effect of foreign currency translation adjustment | — | — | — | — | 2.0 | — | 2.0 | ||||||||||||||||||||
Less cash attributable to discontinued operations | — | — | — | — | (42.5 | ) | — | (42.5 | ) | ||||||||||||||||||
Net (decrease) increase in cash and cash equivalents | — | (3,175.6 | ) | — | 121.5 | 227.1 | — | (2,827.0 | ) | ||||||||||||||||||
Cash and cash equivalents at beginning of year | — | 5,522.2 | — | 5.4 | 92.5 | — | 5,620.1 | ||||||||||||||||||||
Cash and cash equivalents at end of year | $ | — | $ | 2,346.6 | $ | — | $ | 126.9 | $ | 319.6 | $ | — | $ | 2,793.1 | |||||||||||||
Condensed Consolidating Statement of Cash Flows | |||||||||||||||||||||||||||
(in millions) | Express Scripts Holding Company | Express Scripts, Inc. | Medco Health Solutions, Inc. | Guarantors | Non- Guarantors | Eliminations | Consolidated | ||||||||||||||||||||
For the year ended December 31, 2011 | |||||||||||||||||||||||||||
Net cash flows provided by (used in) operating activities | $ | (14.1 | ) | $ | 1,426.4 | $ | — | $ | 753.1 | $ | 27.7 | $ | — | $ | 2,193.1 | ||||||||||||
Cash flows from investing activities: | |||||||||||||||||||||||||||
Purchases of property and equipment | — | (124.9 | ) | — | (13.4 | ) | (6.1 | ) | — | (144.4 | ) | ||||||||||||||||
Other | — | (1.0 | ) | — | 1.3 | 20.2 | — | 20.5 | |||||||||||||||||||
Net cash (used in) provided by investing activities | — | (125.9 | ) | — | (12.1 | ) | 14.1 | — | (123.9 | ) | |||||||||||||||||
Cash flows from financing activities: | |||||||||||||||||||||||||||
Treasury stock acquired | — | (2,515.7 | ) | — | — | — | — | (2,515.7 | ) | ||||||||||||||||||
Repayment of long-term debt | — | (0.1 | ) | — | — | — | — | (0.1 | ) | ||||||||||||||||||
Net proceeds from employee stock plans | — | 32.2 | — | — | — | — | 32.2 | ||||||||||||||||||||
Excess tax benefit relating to employee stock-based compensation | — | 28.3 | — | — | — | — | 28.3 | ||||||||||||||||||||
Distributions paid to non-controlling interest | — | — | — | — | (1.1 | ) | — | (1.1 | ) | ||||||||||||||||||
Proceeds from long-term debt, net of discounts | 4,086.3 | 1,494.0 | — | — | — | — | 5,580.3 | ||||||||||||||||||||
Deferred financing fees | (29.2 | ) | (62.4 | ) | — | — | — | — | (91.6 | ) | |||||||||||||||||
Other | — | (2.9 | ) | — | — | — | — | (2.9 | ) | ||||||||||||||||||
Net intercompany transactions | (4,043.0 | ) | 4,791.6 | — | (744.6 | ) | (4.0 | ) | — | — | |||||||||||||||||
Net cash provided by (used in) financing activities | 14.1 | 3,765.0 | — | (744.6 | ) | (5.1 | ) | — | 3,029.4 | ||||||||||||||||||
Effect of foreign currency translation adjustment | — | — | — | — | (2.2 | ) | — | (2.2 | ) | ||||||||||||||||||
Net increase (decrease) in cash and cash equivalents | — | 5,065.5 | — | (3.6 | ) | 34.5 | — | 5,096.4 | |||||||||||||||||||
Cash and cash equivalents at beginning of year | — | 456.7 | — | 9.0 | 58.0 | — | 523.7 | ||||||||||||||||||||
Cash and cash equivalents at end of year | $ | — | $ | 5,522.2 | $ | — | $ | 5.4 | $ | 92.5 | $ | — | $ | 5,620.1 | |||||||||||||